Backhouse et al. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study. Value in Health. 2011; 14:608-615
Barlas S. Pitting the FDA against CMS: the good, the bad and the ugly about “parallel review”. Biotechnol Health. 2011; 8:29-30
Eichler et al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat. Rev. Drug Discov. 2011; 10:495-506
Henshall et al. Interactions between HTA, coverage and regulatory processes: emerging issues, goals and opportunities. Int. J. Technol. Assess. Health Care; 2011; 27:253-60.
Pignatti et al. Regulators, payers and prescribers: can we fill the gaps? The Lancet Oncology. 2011; 12: 930-931
Eichler et al. Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat. Rev. Drug Discov. 2010; 9:277-91.
1999 – 2009
Battista et al. Health technology assessment and the regulation of medical devices and procedures in Quebec. Int. J. Technol. Assess. Health Care. 1999; 15:593-601
Wang S and Smith J. Potential legal barriers to increasing CMS/FDA collaboration: the law of trade secrets and related considerations. Food and Drug Law Journal. 2003; 58:613-627